As reported by Rashida Barakat in "Epidemiology of Schistosomiasis in Egypt-Travel through Time" *Schistosoma haematobium* was endemic in Ancient Egypt, and although successful control projects have been implemented in the last 50 years, yet neither the number of endemic countries nor the estimated number of people infected or at risk of infection were reduced". Accordingly, nothing could be more irritating and dangerous than the continuous assertions of authorities in the Egyptian Ministry of Health and Population (MOHP) that schistosomiasis is near elimination in Egypt. This is irritating because it is untrue. The assertion is based on analyses of stool or urine, while modern and more accurate techniques are entirely unavailable. Indeed, it is said that 207 million people worldwide are now reported to be infected with schistosomes, while researchers argue that this number is a very gross underestimate because of the limited sensitivity of diagnostic techniques, leading to about 40--60% missed diagnoses. Spreading the word that schistosomiasis is disappearing from Egypt discourages vigilance and compliance to treatment, and leads to increase in number of persons unaware of their infection until death by hematemesis or superinfection with hepatic viruses with all the sequelae. People with insidious schistosomiasis are unable to combat viral infections, and are thus harmed and represent a reservoir for infection of the community. A circumstantial evidence is the superimposition of areas of higher prevalence of hepatitis C virus and regions where schistosomiasis prevails, i.e. the rural areas. This nonstop assertion that schistosomiasis is now a trivial problem in Egypt discourages scientists from developing and implementing accurate diagnostic techniques, alternative drugs, and most importantly vaccines in an aim to truly eradicate this infection not only from Egypt but from the face of the world. Accordingly, this Special Issue on several aspects of schistosomiasis is most timely and precious, reviving the knowledge and interest in this infection, now relegated by the scientific community, including the World Health Organization, to the status of a neglected tropical disease.

The studies reported and discussed by Rashida Barakat in the first Review of this special issue indicate the great success of the Egyptian MOHP in decreasing the prevalence of schistosomiasis mansoni and haematobium from 60% in the years 1930 and 1940 to 3% or less nowadays. However, the last epidemiological studies were performed in 2000, and there are no more recent definite established epidemiological studies. The mass use of praziquantel may have led to changes in the biology of schistosomes perhaps eliciting lower inability of the eggs to exit the human body with consequent inability of detection, and higher amount of eggs lodging in the tissues while unawareness of this dangerous situation is the rule. Accordingly, it is recommended that a national epidemiological study is implemented without delay, provided that modern and accurate immunological and molecular biology diagnostic tools are used beside the Kato-Katz technique.

This issue includes 3 comprehensive and integrated reviews on the clinical aspects of schistosomiasis caused by *Schistosoma mansoni* and *Schistosoma haematobium* by expert leaders who have managed and treated thousands of human cases. The review by Rashad S. Barsoum, Gamal Esmat and Tamer El-Baz, establishes the foundation and documents the concept of a novel perspective for clinical schistosomiasis, whereby clinical manifestations of the disease, the acute, sub-acute and chronic stages, mirror the progression of the host's immune responses to the process of parasite's maturation. In addition to the full, well-illustrated, description of the clinical aspects of schistosomiasis involving primary and secondary targets, the authors elaborate on the major sequelae, namely amyloidosis, malignancy, and bacterial and viral co-infections, and provide the advice of experts for the management and treatment of the disease. In the review "Hepatic and Intestinal Schistosomiasis" by Tamer ElBaz and Gamal Esmat, the disease caused by *S*. *mansoni* is not named hepato-intestinal schistosomiasis, as the authors explain that intestinal schistosomiasis represents a form different from hepatic schistosomiasis, and report on the differences in pathogenesis and clinical manifestation. The authors then discuss their experience with diagnostic techniques and schistosomicidal drugs, and recommend development of an effective vaccine for prevention of the infection and elimination of transmission. In the Review "Urinary Schistosomiasis" by Rashad Barsoum, the clinical manifestations of the disease are displayed from a pathogenetic perspective, and categorized as cellular immunity- and immune complex-mediated disorders. The inflammatory and fibrotic lesions in the different parts of the urinary tract are described in a comprehensive and fascinatingly novel manner. The author then elaborates, in depth, on the immune-complex-related six clinicopathological classes mostly associated with *S*. *mansoni*, and on Schistosoma associated bacterial and viral infections, and bladder neoplasia.

The issue of "Schistosomiasis and Cancer in Egypt" is dealt by Hussein M. Khaled who reviewed the epidemiology, etiology, biological aspects, and clinic-pathologic characteristics of bladder cancer and explained in depth its changing patterns in Egypt, and how these changes affect treatment and management. The author shares his experience and expertise regarding options of radiotherapy and chemotherapy alone or in combination, and recommends gemcitabine-cisplatin regimens for the patients, provided they still have remnants of vigor and fitness. It is obvious that long-term survival rates of patients with invasive disease which range between 30%-50% are largely unsatisfactory. This should enhance efforts for prevention and detection of bladder tumors at early disease stages. This would entail more media campaigns and more close collaboration with health care authorities in the concerned countries. Enhanced vaccine development comes undoubtedly on top of the list of these efforts.

It is miraculous that Rashika El Ridi and Hatem Tallima were able in the midst of all this frustration to relentlessly carry on research on the biology of the lung-stage schistosomula, the documented target of innate and acquired immunity against invading schistosomes, as shown in the last review of this Special Issue. Elucidating the basis of immune evasion in this stage and in adult worms paved the way to development of arachidonic acid as a remedy for schistosomiasis as it is schistosomicidal and an essential nutrient as well. Additionally, proper selection of candidate vaccine antigens and the correct adjuvant led them to open novel avenues for development of an efficacious schistosomiasis vaccine.
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